Lisdexamfetamine

Lisdexamfetamine, dem sell under de brand names Vyvanse den Elvanse among odas, be a stimulant medication wey dem dey use as a treatment for attention deficit hyperactivity disorder (ADHD) insyd kiddies den adults den for moderate-to-severe binge eating disorder insyd adults.  A prodrug of dextroamphetamine, dem dey take lisdexamfetamine by mouth. Ein effects generally dey begin within 90 minutes den dey last for up to 14 hours.

Common side effects of lisdexamfetamine dey include loss of appetite, anxiety, diarrhea, trouble sleeping, irritability, den nausea. Rare buh serious side effects dey include mania, sudden cardiac death insyd those plus underlying heart problems, den psychosis. E get a high potential for substance abuse. Serotonin syndrome fi occur if dem use am plus certain oda medications. Ein use during pregnancy fi result in harm to de baby wey na ein use during breastfeeding no be recommended by de manufacturer.

Lisdexamfetamine be an inactive prodrug wey be formed by de condensation of L-lysine, a naturally wey dey occur amino acid, den dextroamphetamine. Insyd de body, metabolic action dey reverse dis process to release de active agent, de central nervous system (CNS) stimulant dextroamphetamine.

Na dem approve lisdexamfetamine for medical use insyd de United States insyd 2007 den insyd de European Union insyd 2012. Insyd 2023, na e be de 76th most commonly prescribed medication insyd de United States, plus more dan 9million prescriptions. E be a Class B controlled substance insyd de United Kingdom, a Schedule 8 controlled drug insyd Australia, den a Schedule II controlled substance insyd de United States.

 References 

 External links 

Category:Amphetamine
Category:Anorectics
Category:Antihypotensive agents
Category:Aphrodisiacs
Category:Attention deficit hyperactivity disorder management
Category:Codrugs
Category:Drugs wey dey act on de nervous system
Category:Drugs wey Takeda Pharmaceutical Company develop
Category:Ergogenic aids
Category:Euphoriants
Category:Excitatory amino acid reuptake inhibitors
Category:Experimental antidepressants
Category:Nootropics
Category:Norepinephrine-dopamine releasing agents
Category:Pro-motivational agents
Category:Stimulants
Category:Substituted amphetamines
Category:TAAR1 agonists
Category:VMAT inhibitors
Category:Wakefulness-promoting agents
Category:World Anti-Doping Agency prohibited substances
Category:Translated from MDWiki